Topics

FDA Grants Abatacept Breakthrough Designation for Acute GVHD

15:24 EST 4 Dec 2019 | OncLive

The FDA has granted a breakthrough therapy designation for abatacept for the prevention of moderate-to-severe acute graft-versus-host disease in patients who have undergone hematopoietic stem cell transplants from unrelated donors.

Original Article: FDA Grants Abatacept Breakthrough Designation for Acute GVHD

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Abatacept Breakthrough Designation for Acute GVHD"

Quick Search

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...